Genflow Biosci Share Chat (GENF)

Tuesday (June 30) was the highly anticipated calendar cutoff for the SLAB dog trial data collection. In the retail world, a portion of short-term traders always buy in expecting an instant, magical RNS announcement the very next morning (July 1 or July 2).

When that instant news didn't drop, those short-term hands got impatient. They started selling their positions today to chase other moving stocks. This created a wave of retail sell orders hitting the market makers' desks all at once.

2. The 2p Floor Was Absorbency, Not a Crash

While a price drop never looks pretty on the day's chart, look closely at how the book handled that 2.7 million share volume.

In a thin, small-cap stock like Genflow, if 2.7 million shares were dumped into a market with no buyers, the share price would have completely cratered—we would be looking at 1.5p or lower. The fact that the price drifted down but held a firm, flat boundary at 2.00p tells you that massive buying liquidity was waiting at 2p to absorb every single sell order.

The Accumulation Rule: Large investors or institutions who want to build a major position cannot buy 2.5 million shares when the stock is quiet without driving the price through the roof. Instead, they sit at a fixed price floor (2p) and let impatient retail sellers hand them the shares.

3. Market Makers Leveling the Book

Market makers hate carrying risk over the weekend. By marking the final price down to 2p on heavy volume, they effectively shook the tree to clear out any remaining trailing stop-losses. This matches the large block buyers with the sellers, flattens their own internal books, and sets a clean, reset baseline.

The Strategic Takeaway

Nothing about Genflow's actual business changed today. The trial data collection closed on time on Tuesday, and the independent analysis is happening right now behind closed doors.

Today was simply a classic case of short-term retail churn clearing the way for stronger, patient hands who are happy to accumulate cheap shares at the 2p floor before the actual summer catalysts land. The coiling of the spring continues. Keep your eyes on the horizon!

Would be helpful, if only to confirm the share price has beginning an upward trend, which is what I wish to see.

We may be over expecting from the SLAB results, which may turn out to be a damp squid.

If we see deals in the 40s to 500s millions, is the only way we can expect to see a decent re-rate

Be patient twp post camel, you must have missed my following post...Gl;-)

Genflow anticipated trial data and granting of patent in June, and Eric has made clear all will be revealed when they're ready!!! Gl :-)

8th April 2026

The SLAB study remains ongoing, with all dogs continuing to be actively monitored and evaluated. The trial is expected to continue for a further four months, with completion anticipated at the end of July 2026. Additional analyses, including methylation clock (biological age) assessment and muscle histology, are in progress and are expected to provide further mechanistic and quantitative insight into the therapy's impact.

Dr Eric Leire, Chief Executive Officer of Genflow said: "These follow-up observations are important as they extend our understanding beyond initial efficacy and into persistence of effect. The consistency of improvements across multiple functional endpoints, together with the continued absence of safety concerns, strengthens our confidence that SIRT6 gene therapy is delivering a sustained biological impact.

Based on the data observed to date, we believe this supports the positioning of our SIRT6 platform as a potentially disease-modifying approach to addressing age-related decline in companion animals. As the study progresses, we continue to engage with prospective partners across animal health to explore licensing, co-development, and commercialisation opportunities."

22nd June 2026

I want to be clear that the October date reflects the summit calendar, not the pace of our work. There is no delay in our trial or business development efforts.

The timing of the conference slot tells you nothing about the timing of either. As a pre-commercial biotech company, we are deliberate about what we disclose and when we disclose it in order to protect our intellectual property, because premature public disclosure can jeopardise patent rights.

We remain in discussions with animal health companies under confidential agreements, and we continue to analyse data collected in the clinical trial. There is absolutely no delay. Presenting in October does not prevent us from continuing our clinical and business development activities.

It seems we are in the no news = bad news cycle.

There is strong selling today. I would appreciate some more communication from Genflow, at least an updated timeline.

Sounds as if your mate has got the hump!!!???🐪🐪🐪

Do not promote other shares on this forum, ( unless it's before the horse has bolted ) and especially those who spend their time in a Genflow glass half empty mode , which hasn't gone unnoticed!!!! Gl mate :-)

Ps C'mon England...it's coming......,-))))))

That's better filtered those annoying mosquitos.

Yes but we as a group invest in high tech companies.

This is GENFLOW-BIOSCIENCES-PLC forum. Just a reminder.🤣

And ours also.

Well said..

No it isn't, Genflow anticipated trial data and granting of patent in June, yesterday, and Eric has made clear all will be revealed when they're ready!!! Gl :-)

8th April 2026

The SLAB study remains ongoing, with all dogs continuing to be actively monitored and evaluated. The trial is expected to continue for a further four months, with completion anticipated at the end of July 2026. Additional analyses, including methylation clock (biological age) assessment and muscle histology, are in progress and are expected to provide further mechanistic and quantitative insight into the therapy's impact.

Dr Eric Leire, Chief Executive Officer of Genflow said: "These follow-up observations are important as they extend our understanding beyond initial efficacy and into persistence of effect. The consistency of improvements across multiple functional endpoints, together with the continued absence of safety concerns, strengthens our confidence that SIRT6 gene therapy is delivering a sustained biological impact.

Based on the data observed to date, we believe this supports the positioning of our SIRT6 platform as a potentially disease-modifying approach to addressing age-related decline in companion animals. As the study progresses, we continue to engage with prospective partners across animal health to explore licensing, co-development, and commercialisation opportunities."

22nd June 2026

I want to be clear that the October date reflects the summit calendar, not the pace of our work. There is no delay in our trial or business development efforts.

The timing of the conference slot tells you nothing about the timing of either. As a pre-commercial biotech company, we are deliberate about what we disclose and when we disclose it in order to protect our intellectual property, because premature public disclosure can jeopardise patent rights.

We remain in discussions with animal health companies under confidential agreements, and we continue to analyse data collected in the clinical trial. There is absolutely no delay. Presenting in October does not prevent us from continuing our clinical and business development activities.

But the promised data announcement is overdue.

The sp has held firm at this level for weeks, and only shows red at opening because of the after hours UT trades posted most days, UT trade at 2.25p yesterday evening, anyways, very much looking forward to the next UPdate or two, potential transformational game changing news fast approaching!!! Gl :-)

As usual with UK shares, a little bit of a quiet period and the share price just dwindles away daily. Drip Drip Drip.

5% drop is just the Spread as low liquidity .

I'm still around, yes I am very busy, and there is not much to comment on right now. We are waiting for the smoke from the chimney to change colour. One day soon it will, I am trying to be zen about it until then.

Probably a busy chap..

Where's pickedpeck gone these days?

Latest Centenarian Sirt6 Pubmed publication by lead author from University Columbia, another one Genflow's academic partners. Gla :-)

Centenarian SIRT6 variants elevate SIRT6 protein and enhance cellular senescence resistance

Yousin Suh et al. Res Sq. 19th June 2026.

Abstract

Centenarians represent a natural model of delayed human aging, offering a unique opportunity to uncover genetic mechanisms that promote longevity. However, the functional consequences of the genetics variants carried by these long-lived individuals remain poorly characterized in physiologically relevant systems. Here, we introduced two linked missense variants in SIRT6 enriched in Ashkenazi Jewish centenarians into the endogenous SIRT6 locus of human embryonic stem cells and differentiated them into somatic lineages to define their effects in a native genomic context. We revealed that centenarian variants elevated endogenous SIRT6 protein abundance through weakened interaction with vimentin, and altered endogenous SIRT6 enzymatic activities, including enhanced mono-ADP-ribosyltransferase activity and reduced deacetylase activity. Functionally, these variants delayed replicative senescence and conferred resistance to progerin-induced stress, accompanied by preservation of DNA repair gene expression programs and suppression of transposable element derepression. Guided by these findings, we evaluated the translational potential of both genetic and pharmacological interventions, demonstrating that adeno-associated virus (AAV)-mediated delivery of centenarian SIRT6 or pharmacological activation of SIRT6 using fucoidan from Fucus vesiculosus (Fucoidan-FV) partially attenuated aging-associated molecular defects, including genome instability and LINE1 derepression, in progeria fibroblasts. Together, these findings demonstrate that centenarian variants exert multifaceted effects on SIRT6 function to enhance cellular stress resistance, and providing a framework for translating genetic discoveries from long-lived individuals into mechanistic insight and potential gerotherapeutic strategies for healthy aging.

Centenarian SIRT6 variants elevate SIRT6 protein and enhance cellular senescence resistance - PubMed htTps://share.google/MAqQvQhXKFat3Jw4h

Genflow Biosciences (LSE:GENF) does not yet have a formal patent officially granted. However, the company recently announced that the European Patent Office (EPO) has recognized the patentability of its core claims. It is currently in its final pre-grant phase under Article 67(3) of the EPC.

The outstanding muscle biopsy histology and methylation clock (biological age) data for Genflow Biosciences’s SLAB (Sarcopenia and Longevity in Aged Beagles) trial are in progress as of June 2026.

Lets hope PP is correct they already know it works, just a rubber stamping exercise...

Agreed.

With the 4m grant and the money raised via the warrants, I very much doubt it Marty.

I very much hope not, they are well funded at this point.

Hopefully they won't be announcing another round of funding today at the AGM.

AGM Tomorrow, not going anyone going.

AI generated

Genflow Biosciences is not attending the policy-focused A4LI H-SPAN Summit. Instead, their primary industry event is the Animal Longevity Summit (ALOS) in Toronto, Canada, on October 1–2, 2026.

Https://x.com/theA4LI

Https://x.com/moreisdifferent/status/2069767959329873965

Will genflow be attending the A4LI H-SPAN Summit D.C tomorrow

The Road Ahead for Genflow

Genflow Biosciences is at a critical inflection point, with the Animal Longevity Summit in October 2026 serving as a key event that could redefine its trajectory. The compelling interim data from its SLAB dog study, demonstrating both safety and efficacy, positions the company favorably for strategic partnerships in the animal health market. Should the full data confirm these positive trends, Genflow's SIRT6-centenarian gene therapy platform could be validated as a significant player in the broader longevity space, paving the way for its ambitious human health programs. Investors should closely monitor the ALOS presentation and subsequent developments regarding licensing agreements and the advancement of its MASH and glaucoma programs, as these will be crucial determinants of Genflow's future success.

Is Genflow Biosciences on the Cusp of a Longevity Breakthrough

1 week ago

SHARE THIS ON:

Save

Key Takeaways

Genflow Biosciences (LSE:GENF, OTCQB:GENFF) is poised for a significant catalyst with its upcoming presentation of the SLAB clinical study data at the Animal Longevity Summit on October 1-2, 2026, which could validate its SIRT6 gene therapy platform.

Interim results from the dog longevity trial have already demonstrated favorable safety and tolerability, alongside promising improvements in muscle mass, frailty, and overall vitality in aged beagles, setting the stage for potential licensing deals in the multi-billion-dollar animal health market.

Success in canine health could serve as a crucial translational step, validating the SIRT6 platform for broader applications in human age-related diseases like MASH and sarcopenia, unlocking substantial long-term value.

Is Genflow Biosciences on the Cusp of a Longevity Breakthrough?

Genflow Biosciences (LSE:GENF, OTCQB:GENFF), a UK-based biotechnology firm, stands at a pivotal juncture as it prepares to unveil comprehensive data from its pioneering SLAB (Sarcopenia and Longevity in Aged Beagles) clinical study. The highly anticipated presentation at the Animal Longevity Summit (ALOS) in Toronto, Canada, scheduled for October 1-2, 2026, represents a critical near-term catalyst for the company. This event could significantly de-risk its proprietary SIRT6-centenarian gene therapy platform and accelerate its commercialization strategy within the burgeoning animal health sector, with profound implications for its human longevity programs. Given the promising interim safety and efficacy signals already reported, Genflow appears to be building a compelling bull case for investors focused on the rapidly expanding longevity market.

The SLAB study, also known as the GF-1004 dog aging study, is a proof-of-concept clinical trial evaluating the safety and efficacy of Genflow’s gene therapy in elderly dogs. This initiative is not merely a veterinary endeavor; it is designed to serve as a translational bridge to human health applications, leveraging the conserved biological pathways of aging between canines and humans. The upcoming ALOS presentation is expected to provide the full spectrum of results, which could solidify Genflow’s position as an innovator in geroscience and attract crucial partnerships. For a company founded in 2020, reaching this stage with such a novel therapeutic approach underscores its rapid progress and the potential disruptive nature of its technology.

What is the Science Behind Genflow's Dog Longevity Trial?

At the heart of Genflow's therapeutic strategy is the SIRT6-centenarian gene therapy, delivered via its lead compound, GF-1002. SIRT6 is a sirtuin gene known to play a crucial role in DNA repair, metabolic regulation, and resistance to age-related decline. The "centenarian variant" refers to a specific genetic alteration of SIRT6 found in humans who live

If on the completion of human trials if we can prevent illnesses happening and extend a more healthy human life span this will open up other advantages. We as humans cannot live on earth for eternity and will have to travel to other planets to preserve the species NASA scientists would tell you that themselves. These human trials forthcoming could have more importance to the existence of mankind than many think.

Great to see the price moving up to 2.25p this morning as the market starts digesting the sheer volume of milestones hitting us over the next few weeks.

I did a bit of digging with the help of the AI and If you want to understand the true "macro" picture of why Gad was invited to speak on that premier RNA stage this week, you have to look at a massive piece of US legislation causing a frenzy behind the scenes: The BIOSECURE Act.

This law forces Western pharma giants to completely sever ties with Chinese contract research and manufacturing giants (like WuXi AppTec). Big Pharma is in a blind panic, rapidly "friend-shoring" and pulling their drug pipelines out of China. They are legally obligated to find secure, patented, Western-aligned platforms to partner with.

This places Genflow in an incredibly lucrative position for two reasons:

1. Zero Regulatory Risk: Genflow is UK-based and completely insulated from these US-China geopolitical risks. Crucially, their major delivery collaboration is with Acuitas Therapeutics—the absolute gold-standard, Canadian global leader in lipid nanoparticle (LNP) tech. For a US or European pharma giant, Genflow is a 100% safe, legally compliant ecosystem to license.

2. The Premium on SIRT6 IP: Because Big Pharma can no longer easily or cheaply outsource discovery work to blacklisted Chinese labs, the value of proprietary, highly specialized Western intellectual property—like Genflow's unique SIRT6 variants and muscular disease patents—has skyrocketed.

The Bottom Line for the AGM on Monday:

When Gad was conducting his private, one-on-one partnering meetings in San Diego this week, he wasn't just pitching good science. He was sitting across from desperate corporate development heads who have the budgets, are legally mandated to source Western genetic tech, and know Genflow's SLAB trial physically concludes this month.

With Eric Leire confirming the unblinded efficacy data is dropping well before October, the leverage is entirely in Genflow's hands. The smart money dropping block buys this week sees the writing on the wall.

Bring on Monday's AGM. GLA! 🚀

“Why Is LSE:GENF Trending Across Google Finance and Yahoo Finance Today?

Genflow Biosciences emerged among today's notable FTSE gainers as investors increased exposure to innovative biotechnology companies focused on next-generation therapies.

Healthcare and biotechnology stocks generally benefit when investors become more comfortable taking long-term growth positions. Today's broader market environment favoured companies with significant future commercial potential, particularly those operating within rapidly expanding medical innovation sectors.

Investor attention continues to centre on longevity research, precision medicine and gene-based therapies, areas expected to attract substantial scientific investment over the coming decade. Although biotechnology companies often experience elevated volatility, periods of improving market sentiment frequently result in strong share price appreciation.

The rally also reflects broader optimism across global healthcare equities as investors seek exposure to industries with structural long-term growth independent of traditional economic cycles.”

https://kalkine.co.uk/news/healthcare/why-is-genflow-biosciences-one-of-todays-biggest-ftse-aim-winners

Genflow are named as a leader in longevity, alongside alphabet (calico labs / google)

https://konsalidon.com/frontier-technologies/longevity-healthspan

“The Genflow Breakthrough: Genflow Biosciences’ SIRT6 gene therapy SLAB study reported superior survival, improved muscle mass, and better coat condition in beagles aged 10+ using a centenarian gene variant.”

https://www.tonyhunterspeaker.com/the-pet-longevity-lab-why-our-1-3-billion-best-friends-are-leading-the-bio-revolution/

I expected him to sell at 200p, but he's adamant FTC will rise to 500p.

If he’s sat on £9m, he could have bought the entire free float of Genflow no probs 🤣

I am part of small group of investors, we hold a total amount of nearly 7 million shares between us, in genflow. We have been highly successful with our previous investments, particularly FTC, where one of us is sitting on nearly £9 million, having bought in at 8p.

Another 184,000

Feeling confident with this one

By the way, thanks for some brilliant updates by most of you guys, much appreciated 👍

Lets hope the market is finally getting the message, lots to look forward too

Lovely jubbly

Gad's presentation gets a mention towards the end of Eric's interview, where he highlights how the move to LNP mRNA delivery technology, allows for repeat dosing, which isn't possible with AAV technology , and so all of Genflow's programs are moving to LNP- mRNA delivery, allowing for repeat dosing, whereby tissue targeted and the natural biological process of cell division, allows repeat dosing into the new cells created, which has no doubt caught the attention of every Tier 1 Animal Healthcare Company, who will be eager to secure a 1st in class therapy for healthspan and longevity, especially one that can be administered on a regular basis throughout the life of the dog under treatment. Ker-Ching!!! Gla ;-)

Agree, we thought 0.06 was cheap, now this is the new cheap. Could easily do 4-5 bags again imo on very little news where the float gets tighter by the day. Wonder if we’ll get another RNS tomorrow before Gad does his panel?

Everything is getting meticulously lined up. Very clean biotech. What amazes me it's still very cheap to buy.

Positive Muscle Histology and Methylation Clock Data fast approaching!!! Gla holders:-)

"Looking ahead, Leire said investors should watch for findings on both sarcopenia and longevity"

I am OK, just keen to see this moving forward, conformation of my original decision to invest was indeed the correct one.

Cheer up Marty

Still waiting on the MC and histology results.

CEO Dr Eric Leire joined Proactive's Stephen Gunnion to discuss the company's upcoming presentation at the Animal Longevity Summit in Toronto, where it will showcase results from its Age Dogs trial evaluating centenarian SIRT6 gene therapy.

Leire said the invitation to present at the independent scientific event offers important external validation of Genflow's methodology and data quality, giving leading scientists and longevity researchers the chance to scrutinise the dataset. He stressed the October timing reflects the conference schedule rather than any delay, with the company continuing to analyse trial data and hold confidential discussions with animal health companies.

Looking ahead, Leire said investors should watch for findings on both sarcopenia and longevity, and how results from aged dogs could translate into Genflow's human sarcopenia programme. "We demonstrated that we have efficacy in mice. Now, we demonstrated that we have efficacy in dogs," he said. "What about human and how can we extrapolate this data from this dog study into human use."

Offgrid, you’re right with the deals. The first deal has already announced today and is noted to be worth billions. Looking good!

“SK biopharmaceuticals has signed a joint research agreement with Insilico Medicine to discover drug candidates for neuroimmune diseases affecting the central nervous system (CNS), in a deal carrying potential milestone payments of up to $2.57 billion and a $4.5 million upfront payment, the company said Monday.

The companies announced the agreement at the BIO International Convention 2026 in Boston.”

https://www.koreabiomed.com/news/articleViewAmp.html?idxno=32129

True and not as old as me, 60s.

Moneymunch, Licensing deals and partnerships are actively formed and announced at the BIO International Convention.

We all know thats why Gad joined the Board in the first place and why he's going to be there, he's the dealmaker.

Probably has a day job

Where's PP?

The BIO International Convention 2026 features a heavy presence from global pharmaceutical giants acting as major event sponsors, high-level presenters, and spotlight partnering companies.

Major Pharma Headliners & Sponsors

The top-tier "Double Helix" and "Helix" level sponsors anchors the event with a massive presence on the exhibition floor and within the partnering networks:

Pfizer — Presenting dedicated organizational and sourcing sessions.

Eli Lilly and Company — Hosted by Tim Luker, PhD (VP Lilly Ventures), presenting on cross-functional therapeutic investments.

Merck — Participating as a premium Double Helix sponsor.

Sanofi — Supporting as a high-level sponsor and an integrated partnering spotlight company.

Amgen — Presenting formal company pipelines and acting as a central hub for the event's business development tracks.

Boehringer Ingelheim — Supporting as a lead Helix sponsor with heavily focused partnering modules.

Key Presenting & Partnering Giants

Several other top-20 global biopharma companies are explicitly locked into the event's high-level schedule through executive speakers, presenting slots, and corporate spotlights:

Johnson & Johnson — Actively participating with executive presence, including insights from John Reed, MD, PhD (Executive VP, Corporate R&D).

Roche / Genentech — Highlighted through "Partnering Spotlights" alongside transactional presentations led by Barbara Lückel, PhD (Global Head of Research Technologies Partnering) and Gregg Talbert (Senior VP, Corporate Business Development).

Takeda — Sponsoring major segments with executive presentations by Christopher Arendt, PhD (Chief Scientific Officer) on oncology and neuroscience pipelines.

Novo Nordisk — Functioning as a high-profile partner spotlight and presenting company.

GlaxoSmithKline (GSK) — Scheduled through data and AI partnering tracks led by Daniyal Hussein (Executive Director, Technology Business Development).

Novartis — Sponsoring clinical data and safety strategy sessions led by Jamie Geier, PhD (Global Head of Quantitative Safety).

AstraZeneca — Active across corporate sponsorships and late-stage process development workshops spearheaded by Mahesh Bule (Director of Late-Stage Process Development).

Bristol Myers Squibb (BMS) — Presenting international healthcare policy and market access strategies through Andrew Whitehead (VP, International Market Access).

Chugai Pharmaceutical — Attending and formally listed as a presenting corporate entity.

bio san diego - genflow bio chairman gad berdugo will be participating in an mrna panel during the event. the panel is scheduled for tuesday, june 23, from 7:30am to 9:00am pacific time.

https://www.***************************/genflow-biosciences-to-attend-bio-san-diego-as-chairman-gad-berdugo-joins-mrna-panel/4121254235

6p is realistic, on good news.

57p by Wednesday.

No, I'm in for the long term, upto 3 year's, as long as it takes. I would feel much more comfortable to see higher volumes and share price.

No offense Marty but pointless speculating, nobody know firstly if a deal will be forthcoming, I strongly believe it will, secondly nobody knows if it will be an outright purchase of the dog program or the more traditional upfront with milestones. If your looking for a quick conclusion to the final outcome of Genflow you will need to be patient, I note from some of your previous posts you want quick outcomes and we all do however the biotech world is very slow with much red tape and Eric will never try to take any short cuts which is of course the correct way to progress. I have been in for 2 years and have a fair chunk, my expectations are we get to a final conclusion of a takeover within 3 years my hope is something happens much sooner. Many will sell on a dog deal but for me that’s short sighted the other programs are vastly larger and where the brave will win big or of course lose, that’s the game your choice if you want to play or cash out on the first run

What are your expectations on a future share price on receipt of good news. I for one believe a jump to 6p is very likely, with steady rises in the coming weeks..

Genflow plc possibly share price re rate +9 Genflow Biosciences PLC (LSE:GENF) is a preclinical biotechnology company developing gene therapies for age-related diseases. The stock trades on the London Stock Exchange (LSE) and is currently priced between 2.05p and 2.15p, with a market capitalization of approximately £11.78M.Current Share Price & PerformanceLast Traded/Current Price: 2.05p - 2.15p52-Week Range: 0.55p to 3.12pMarket Capitalization: ~£11.78 millionYear-to-Date (YTD): GENF is up ~12–16%, though short-term volatility remains.Potential Catalysts for a Re-RatingThe market's valuation of a pre-revenue biotechnology company typically shifts ("re-rates") based on clinical milestones, IP expansion, and commercial partnerships. Key drivers for Genflow include:Canine Longevity Trials: The company has reported promising interim safety and efficacy data from its SIRT6 gene therapy trial in aged dogs. Continued positive data could trigger a major re-rate as it validates the technology platform in large animals.Corporate Partnerships: Genflow has expanded confidentiality agreements with major global animal health companies and established delivery deals. Entering into definitive development or licensing agreements would provide non-dilutive capital and commercial validation.Pipeline Progress: Progression of its flagship human compound, GF-1002 (targeting the SIRT6 variant to slow the aging process), into further stages of development.Cash Runway: Biotech re-ratings are closely tied to liquidity. The company successfully raised £800,000 and confirmed receipt of a €4 million grant installment to fund ongoing programs.You can track real-time price movements and view official announcements using Yahoo Finance UK, the London South East platform, or via the London Stock Exchange.Would you like me to dive deeper into Genflow's financial runway, the specifics of their SIRT6 gene therapy, or the competitive landscape for age-related biotech?Genflow Biosciences plc (GENF.L) latest stock news and headlinesGenflow Biosciences plc (GENF. L) * Genflow surges 14% as animal health giants circle canine ageing gene therapy. ... * Genflow widens confidentiality agreement...Yahoo Finance UKGenflow Biosciences plc (GENF.L)GENF.L. Genflow Biosciences plc. 2.0800. +0.24% Mkt cap GBp 11.781M. Industry Biotechnology. CIZ.L. Cizzle Biotechnology Holdings Plc. 2.7000. -5.26% Mkt cap GB...Yahoo Finance UKGenflow Biosciences Share Price | GENF StockWhat Is the Genflow Biosciences PLC Share Price Today? The Genflow Biosciences share price today is 2.08. What Is the Stock Symbol for Genflow Biosciences PLC. ...Investing.com UKGenflow Biosciences Share Price Forecast (GENF)

Let's hope you're right..

The SLAB Trial Final Data Publication along with granting of Patent, are both anticipated this month according to Genflow’s recent LinkedIn post. All bodes well for a Major re-rate and every chance one of the Tier-1 Animal Healthcare companies could make a move, which no doubt could see the sp at multiples of current bargain low. Gla holders, game changing news at anytime!!! :-)

Thanks I have requested to Join

This is a fascinating research and does look that when the Methylation Clock is done in July and presented in October there be a lot of interest .

I been lurking here for a while.

I have requested to join also

EL stated back in February results were two months away. Didn't happen so what's gone wrong?

Cognition Therapeutics secu...

AlzeCure clears key hurdle ...

Resolution Therapeutics ext...

ProJenX completes enrollmen...

Qihan Biotech cell therapy ...

Cognition Therapeutics secu...

AlzeCure clears key hurdle ...

Resolution Therapeutics ext...

ProJenX completes enrollmen...

Qihan Biotech cell therapy ...

Biotech

Feb 12, 2026

Genflow reveals early data from SIRT6 gene therapy trial in dogs

Danny Sullivan

Preliminary results indicate that treated animals demonstrated ‘superior survival’ and functional improvements compared to the control group.

It’s a good week to be a dog. Hot on the heels of Loyal raising $100m to gear up for commercialization of its canine longevity drug, longevity biotech Genflow Biosciences today announced preliminary interim findings from a clinical study evaluating its SIRT6 gene therapy in aged dogs. The London-based company, founded in 2020 to develop gene therapies targeting age-related disease, sees the program as both an opportunity in companion animal health and a stepping stone toward human applications.

The SIRT6 gene has attracted significant attention in the longevity field because of its role in DNA repair and genome stability, and research indicating that enhancing its activity may influence lifespan and resilience in animal models. By first applying its technology in companion animals, Genflow hopes to build clinical evidence that could also inform human therapeutic development.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Email Address(Required)

Enter Your Email Address

CAPTCHA

Today’s data come from the SLAB (Sarcopenia and Longevity in Aged Beagles) trial, where 24 beagles aged 10 years or older were enrolled and assigned across four groups, including two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and an untreated control arm. The proof-of-concept study was first announced last year and focuses on assessing whether delivery of a variant of the SIRT6 gene can mitigate functional decline associated with aging.

According to the interim analysis announced by Genflow today, all treatment groups showed “superior survival” compared with the control animals during the dosing period. Beyond survival outcomes, the company says that treated animals displayed improvements across several functional indicators, including quality of life measures, maintenance of muscle mass, reductions in frailty scores and visible changes such as coat condition. Control animals followed a more typical trajectory of age-related decline.

Dr Eric Leire, founder and CEO of Genflow Biosciences

“The consistency of positive signals across multiple independent endpoints from survival and quality of life to measures of muscle preservation and frailty reduction, combined with an excellent safety profile, supports our SIRT6 platform as a credible, differentiated asset for the companion animal market,” said Genflow C